Protalix BioTherapeutics Q2 2026 profit, revenue surge
Protalix BioTherapeutics, Inc. reported substantially stronger results for the quarter and six months ended June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Protalix BioTherapeutics, Inc. reported substantially stronger results for the quarter and six months ended June 30, 2026. Total revenue for the first half of 2026 was $53.6 million, up from $25.8 million in 2025, and net income turned to a $22.1 million profit from a $3.5 million loss. Second quarter 2026 revenue was $19.9 million versus $15.7 million a year earlier, with net income of $3.8 million versus $0.2 million.
Growth was driven by higher revenues from selling goods, primarily continued global penetration of Elfabrio, and a $25.0 million milestone payment from Chiesi related to EU dosage approval. Cash and cash equivalents plus short-term deposits totaled $40.7 million at June 30, 2026, and the company states it has no outstanding debt or warrants. Management reaffirmed its 2026 revenue expectations and highlighted progress in the PRX-115 Phase 2 RELEASE trial and preclinical programs focused on rare renal indications, while indicating that future license and R&D service revenues are expected to be minimal aside from potential regulatory milestones.
Positive
- Total revenue for the first half of 2026 rose to $53.6 million from $25.8 million a year earlier, more than doubling year over year.
- The company moved from a $3.5 million net loss in the first half of 2025 to a $22.1 million net profit in the first half of 2026.
- Second quarter 2026 net income increased to $3.8 million from $0.2 million in the prior-year quarter, reflecting stronger profitability.
- Cash and cash equivalents plus short-term deposits reached $40.7 million at June 30, 2026, and the company reports no outstanding debt or warrants.
- The company received a $25.0 million milestone payment from Chiesi tied to EU dosage approval for Elfabrio, boosting first-half revenue and income.
- Management reaffirmed its 2026 revenue expectations, signaling confidence in the current outlook.
Negative
- Revenues from license and R&D services for the second quarter fell to $0.1 million from $0.2 million a year earlier, and the company expects minimal such revenues going forward aside from potential milestones.
Filing Explained
The
8-K Event Classification
Key Figures
Key Terms
milestone payment financial
Phase 2 RELEASE clinical trial medical
enzyme replacement therapies medical
operating lease liabilities financial
boxed warning regulatory
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Protalix BioTherapeutics (PLX) perform financially in the first half of 2026?
What were Protalix BioTherapeutics (PLX) second quarter 2026 results?
What is driving Protalix BioTherapeutics (PLX) revenue growth in 2026?
What is Protalix BioTherapeutics’ (PLX) cash position and debt level?
How important are license and R&D service revenues for Protalix BioTherapeutics (PLX)?
What clinical programs did Protalix BioTherapeutics (PLX) highlight in this update?
Did Protalix BioTherapeutics (PLX) change its 2026 revenue outlook?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Item 2.02 Results of Operations and Financial Condition
On August 12, 2026, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026 and provided a business and clinical update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
Exhibit No. |
| Description |
99.1 | Press Release dated August 12, 2026 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 12, 2026 | PROTALIX BIOTHERAPEUTICS, INC. | ||
|
|
|
|
| By: | /s/ Dror Bashan | |
|
| Name: | Dror Bashan |
|
| Title: | President and Chief Executive Officer |
| Exhibit 99.1 |
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT
| ● | Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® |
| ● | Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment |
| ● | Year-to-date, the Company achieved profitability with a net income of $22.1 million |
| ● | The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue |
| ● | PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 |
| ● | Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 |
CARMIEL, Israel, August 12, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.
During the second quarter, Protalix grew revenues from selling goods, driven primarily by continued penetration of Elfabrio® globally, advanced enrollment in the PRX-115 Phase 2 RELEASE clinical trial, and reaffirmed its strategic priorities and financial outlook for 2026.
"We enter the second half of 2026 in a position of strength, driven by the continued penetration and growth of Elfabrio® through our partnership with Chiesi, a trend toward achieving our financial goals for 2026," said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. "Total revenue climbed to $53.6 million from $25.8 million for the same period in 2025. With $40.7 million in cash and short-term deposits, we are well-positioned to fund execution across our operations. We remain focused on continued enrollment in our PRX-115 Phase 2 RELEASE study and our pipeline addressing rare renal indications."
Second Quarter 2026 Operational Update
Elfabrio® for Fabry Disease
| ● | On May 4, 2026, the U.S. Patent and Trademark Office (USPTO) issued a Patent Term Extension certificate for U.S. Patent No. 9,194,011, covering Elfabrio® (pegunigalsidase alfa-iwxj). The extension adds five years to the patent term, moving the U.S. expiration date to November 17, 2035. |
| ● | Elfabrio® received orphan drug designation and Marketing Authorization in South Korea in May 2026, with Kwangdong Pharmaceutical Co., Ltd. as the local marketing authorization holder. |
PRX-115 for Uncontrolled Gout – RELEASE Phase 2 continues enrollment
| ● | On July 7, 2026, the USPTO issued U.S. Patent No. 12,674,146, "Modified Uricase and Uses Thereof," to Protalix Ltd., strengthening the Company's intellectual property position around PRX-115. |
| ● | Patient enrollment continues in the Company’s RELEASE Phase 2 clinical trial (NCT07280156) of PRX‑115, a recombinant PEGylated uricase, for the treatment of uncontrolled gout. |
| ● | The Company continues to anticipate top‑line results in the second half of 2027. |
Focus on Rare Renal Indications (Preclinical Programs)
| ● | The Company continues to advance PRX‑119, its long‑acting DNase I program, as part of a broader strategic focus on rare renal indications, as well as other research collaborations. |
Financial Outlook: Building Durable Growth and Long–Term Value
The Company operates a profitable growing commercial business through its partnerships, and a focused pipeline aligned to areas of high unmet need. The Company has a strong balance sheet, with no outstanding debt or warrants. The Company believes that its current business model limits downside risk while preserving significant upside potential as the Company progresses its clinical and preclinical programs, expands its commercial footprint, and pursues strategic partnerships to accelerate impact and scale.
Priorities remain consistent:
| 1. | Support our commercial partners through the manufacture and supply of our products |
| 2. | Advance PRX–115 as a potential best–in–class therapy for patients with uncontrolled gout |
| 3. | Advance rare renal programs leveraging the Company’s R&D strengths |
The Company reaffirms its previously stated 2026 revenue expectations:
| ● | Total revenue in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million milestone which the Company has received from Chiesi. |
| o | Full‑year 2026 revenues from sales of Elfabrio® without milestones to range from approximately $33.0 million to $35.0 million. |
| o | Full‑year 2026 revenues from sales of Elelyso® to range from approximately $20.0 million to $23.0 million. |
This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. These estimates are based on management’s current estimates, which are subject to change and may be updated accordingly. See “Forward-Looking Statements” for additional information.
Second Quarter and Year-to-Date 2026 Financials highlights
| ● | Revenues from selling goods were $19.8 and $27.2 million for the three and six months ended June 30, 2026, respectively compared to $15.4 and $25.4 million for |
| the same periods in 2025, respectively, an increase of $4.4 and $1.8 million, respectively. The increase was driven primarily by higher sales to Chiesi and Fiocruz (Brazil), partially offset by lower Pfizer purchases mainly due to Pfizer's manufacturing issues in the previous year. |
Revenues from license and R&D services were $0.1 and $26.4 million for the three and six months ended June 30, 2026, respectively, compared to $0.2 and $0.3 million for the same periods in 2025, the decrease in the second quarter was due to a lower amount of services provided to Chiesi in the second quarter of 2026. The increase in the first half of 2026 resulted from the $25.0 million milestone payment received from Chiesi in connection with the E4W dosage approval in the EU in the first quarter of 2026. Other than potential regulatory milestone payments, the Company expects to generate minimal revenues from license and R&D services going forward, having completed the clinical development of Elfabrio®.
| ● | Cost of revenues were $7.8 and $11.9 million for the three and six months ended June 30, 2026, respectively, an increase of $1.9 million (32%) and a decrease of $2.2 million (15%) compared to $5.9 and $14.1 million for the same periods in 2025. The increase in the second quarter was driven primarily by higher sales to Chiesi and Fiocruz (Brazil), partially offset by lower sales to Pfizer. The decrease in the first half of 2026 resulted primarily from a decrease in sales to Pfizer which was partially offset by an increase in sales to Chiesi and to Fiocruz (Brazil). |
| ● | Research and development (R&D) expenses were $4.4 and $9.8 million for the three and six months ended June 30, 2026, respectively, a decrease of $1.6 million and an increase of $0.3 million compared to $6.0 and $9.5 million for the same periods in 2025. Both periods reflect a $2.1 million grant receivable recorded under the new R&D law as a reduction of R&D expenses. The Company expects to continue to incur R&D expenses as the RELEASE study progresses and additional preclinical and clinical programs advance. |
| ● | Selling, general, and administrative (SG&A) expenses were $3.1 and $6.2 million for the three and six months ended June 30, 2026, respectively, an increase of $0.5 and $1.0 million, respectively, compared to $2.6 and $5.2 million for the prior-year periods, driven primarily by $0.3 and $0.7 million in higher salary and related expenses, respectively, and of $0.2 million higher selling expenses for the three and six months ended June 30, 2026. |
| ● | Financial income, net was $0.2 million for the three and six months ended June 30,2026, compared to financial expenses, net of $0.5 and $0.1 million for the same periods in 2025. The change resulted primarily from exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel. |
| ● | Taxes on income were $1.1 and $3.9 million for the three and six months ended June 30, 2026, respectively, compared to $0.5 and $0.4 million for the same periods in 2025 an increase of $0.6 and $3.5 million, respectively. The increase resulted primarily from taxes on income derived from global intangible low-taxed income |
| (GILTI) resulting from limitations under IRC Section 174 and from taxes related to the Company’s receipt of the $25 million milestone payment in the first quarter of 2026. |
| ● | Cash, cash equivalents, and short‑term bank deposits were $40.7 million at June 30, 2026. |
| ● | Net income for the three months ended June 30, 2026 was $3.8 million or $0.05 per share, basic and diluted, compared to net income of $164,000 or $0.00 per share, basic and diluted, for the same period in 2025. Net income for the six months ended June 30, 2026 was $22.1 million, or $0.28 per share, basic, and $0.27 per share, diluted, compared to a net loss of $3.5 million, or $0.04 per share, basic and diluted, for the same period in 2025. |
Conference Call and Webcast Information
The Company will host a conference call today, August 12, at 8:00 am EDT, to review the financial results and provide a business update. To participate in the conference call, please dial the following numbers prior to the start of the call:
Conference Call Details:
Date: August 12, 2026
Time: 8:00 a.m. Eastern Daylight Time (EDT)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13761985
Call me™: https://bit.ly/4w2Over
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: http://bit.ly/4h4mqOY
Conference ID: 13761985
Participants are requested to access the websites at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Protalix website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed
through Protalix’s proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix’s development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements generally relate to future events or the Company’s future financial or operating performance, including the 2026 financial outlook described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. The terms “anticipate,” “believe,” “estimate,” “expect,” “can,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings of the clinical trial. Factors that might cause material differences include, among others: risks related to the commercialization of Elfabrio® (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease; risks relating to Elfabrio’s market acceptance, competition, reimbursement, and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; risks related to the regulatory approval and commercial success of our other product and product candidates, if approved; risks related to our expectations with respect to the projected market of our products and product candidates; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and/or inability to monitor patients adequately during or after treatment; the risk that the results of our clinical trials of our product candidates will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; the possible disruption of our operations due to the
regional conflict in Iran and the military actions between Israel and Iran, the Hamas terrorist organization located in the Gaza Strip, Hezbollah, the Houthis terrorist group that controls parts of Yemen, and others, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors, and customers, and the risk that the current hostilities will result in increased regional conflict; delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency or other health regulatory authorities for our other product candidates and other risks relating to the review process; risks associated with global conditions and developments such as new or increased tariffs, treaties, trade policies, taxes, and other limitations on cross-border operations, which may adversely impact our business, results of operations, and financial condition; risks associated with global conditions and developments such as new or changed trade restrictions, supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, results of operations, and financial condition, and our ability to raise additional financing if and as required and on terms acceptable to us; risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; risks relating to our evaluation and pursuit of strategic partnerships; risks relating to our ability to manage our relationship with our collaborators, distributors, and partners, including, but not limited to, Pfizer Inc. and Chiesi Farmaceutici S.p.A.; risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits; risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish; risks relating to the compliance by Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health with its purchase obligations under our supply and technology transfer agreement that we entered into with Fiocruz in June 2013, which may have a material adverse effect on us and may result in our terminating such agreement; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; risks related to our supply of drug products to Pfizer; potential product liability risks, and risks of securing adequate levels of related insurance coverage; the possibility of infringing a third-party’s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law. You are cautioned not to place undue reliance on these forward-looking statements.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Unaudited)
| | June 30, 2026 | | December 31, 2025 | ||
| | | | | | |
ASSETS | | | | | | |
| | | | | | |
CURRENT ASSETS: | | | | | | |
Cash and cash equivalents | | $ | 27,420 | | $ | 14,680 |
Short-term bank deposits | | | 13,236 | | | 15,593 |
Restricted deposit | | | 720 | | | 702 |
Accounts receivable | |
| 16,503 | |
| 8,840 |
Other assets | |
| 2,049 | |
| 1,129 |
Inventories | |
| 32,292 | |
| 25,729 |
Total current assets | | $ | 92,220 | | $ | 66,673 |
| | | | | | |
NON-CURRENT ASSETS: | | | | | | |
Funds in respect of employee rights upon retirement | | $ | - | | $ | 578 |
Property and equipment, net | |
| 5,467 | |
| 4,879 |
R&D grant receivable | | | 2,100 | | | - |
Deferred income tax asset | | | 2,374 | | | 2,516 |
Operating lease right of use assets | |
| 8,175 | |
| 7,700 |
Total assets | | $ | 110,336 | | $ | 82,346 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | |
| |
| | | | | | |
CURRENT LIABILITIES: | |
| | |
| |
Accounts payable and accruals: | |
| | |
| |
Trade | | $ | 6,506 | | $ | 5,259 |
Other | |
| 23,219 | |
| 19,875 |
Operating lease liabilities | |
| 1,666 | |
| 1,384 |
Total current liabilities | | $ | 31,391 | | $ | 26,518 |
| | | | | | |
LONG TERM LIABILITIES: | |
| | |
| |
Liability for employee rights upon retirement | | $ | - | | $ | 661 |
Operating lease liabilities | |
| 7,541 | |
| 6,937 |
Total long-term liabilities | | $ | 7,541 | | $ | 7,598 |
Total liabilities | | $ | 38,932 | | $ | 34,116 |
| | | | | | |
COMMITMENTS | | | | | | |
| | | | | | |
STOCKHOLDERS’ EQUITY | | | 71,404 | | | 48,230 |
Total liabilities and stockholders’ equity | | $ | 110,336 | | $ | 82,346 |
PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
(Unaudited)
| | Six Months Ended | | Three Months Ended | ||||||||||||||||
| | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025 | ||||||||||||
REVENUES FROM SELLING GOODS | | $ | 27,247 | | $ | 25,435 | | $ | 19,828 | | $ | 15,440 | ||||||||
REVENUES FROM LICENSE AND R&D SERVICES | |
| 26,399 | |
| 336 | |
| 68 | |
| 218 | ||||||||
TOTAL REVENUE | | | 53,646 | | | 25,771 | | | 19,896 | | | 15,658 | ||||||||
COST OF REVENUES | |
| (11,889) | |
| (14,050) | |
| (7,762) | |
| (5,870) | ||||||||
RESEARCH AND DEVELOPMENT EXPENSES, NET | |
| (9,777) | |
| (9,467) | |
| (4,351) | |
| (5,992) | ||||||||
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | |
| (6,162) | |
| (5,227) | |
| (3,111) | |
| (2,624) | ||||||||
OPERATING INCOME (LOSS) | |
| 25,818 | |
| (2,973) | |
| 4,672 | |
| 1,172 | ||||||||
FINANCIAL EXPENSES | |
| (665) | |
| (628) | |
| (494) | |
| (783) | ||||||||
FINANCIAL INCOME | |
| 848 | |
| 530 | |
| 682 | |
| 272 | ||||||||
FINANCIAL INCOME (EXPENSES), NET | |
| 183 | |
| (98) | |
| 188 | |
| (511) | ||||||||
INCOME (LOSS) BEFORE TAXES ON INCOME | | | 26,001 | | | (3,071) | | | 4,860 | | | 661 | ||||||||
TAXES ON INCOME | | | 3,907 | | | 384 | | | 1,083 | | | 497 | ||||||||
NET INCOME (LOSS) | | $ | 22,094 | | $ | (3,455) | | $ | 3,777 | | $ | 164 | ||||||||
EARNINGS (LOSS) PER SHARE OF COMMON STOCK: | | | | | | | | | | | | | ||||||||
BASIC | | $ | 0.28 | | $ | (0.04) | | $ | 0.05 | | $ | 0.00 | ||||||||
DILUTED | | $ | 0.27 | | $ | (0.04) | | $ | 0.05 | | $ | 0.00 | ||||||||
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK | | | | | | | | | | | | | ||||||||
USED IN COMPUTING EARNINGS (LOSS) PER SHARE: | | | | | | | | | | | | | ||||||||
BASIC | |
| 79,884,562 | |
| 77,651,330 | |
| 79,986,325 | |
| 78,663,884 | ||||||||
DILUTED | | | 82,810,511 | |
| 77,651,330 | | | 82,560,235 | |
| 81,271,610 | ||||||||